Skip to main content
Premium Trial:

Request an Annual Quote

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

NEW YORK – BGI Genomics said on Thursday that it has received CE marking for two multiplexed tests for SARS-CoV-2 and influenza A/B produced by its subsidiary BGI PathoGenesis Pharmaceutical Technology.

Both real-time fluorescent RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples using a single reaction. One test detects the SARS-CoV-2 ORF1ab gene, while the second test detects the virus's ORF1ab and N genes.

As the clinical symptoms of influenza A and influenza B infection and COVID-19 are similar, the new multiplex tests can help rapidly triage testing populations, BGI said.

In March, BGI garnered CE marking for its Real-Time Fluorescent RT-PCR kit for SARS-CoV-2, while its BGI Americas subsidiary received US Food and Drug Administration Emergency Use Authorization for the same test.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.